Biochemical and immunohistochemical estrogen and progesterone receptors in adenomatous hyperplasia and endometrial carcinoma: Correlations with stage and other clinicopathologic features

Nyholm, Henrik Christian Juul; Nielsen, Anne Bjerg; Lyndrup, Jens; Norup, Peter; Thorpe, Susan M.

doi:10.1016/0020-7292(93)90491-e

Cited by 7 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In diffuse forms of hyperplasia, compared with proliferative endometrium or carcinoma, both oestrogen and progesterone receptors are increased. 7 This explains why progestins are effective in suppressing hyperplasia. However, most cases of endometrial hyperplasia are not precancerous and only atypical hyperplasia can effectively progress to carcinoma.…”

Section: Discussionmentioning

confidence: 99%

Histopathology and steroid receptors in endometrial polyps of postmenopausal patients under hormone‐replacement therapy

Maia¹,

Maltez²,

Calmon³

et al. 1998

Gynaecol Endoscopy

View full text Add to dashboard Cite

Objective To study the histopathology of endometrial polyps that had developed during 6–18 months of hormone‐replacement therapy (HRT), and to determine the status of oestrogen and progesterone receptors in these lesions. Design Retrospective study. Subjects Fifty‐five menopausal patients receiving HRT who had endometrial polyps. Interventions Polypectomy followed by endometrial resection. Results Endometrial polyps have foci of hyperplasia that do not respond to progestin in menopausal patients receiving HRT. This is associated with lack of progesterone receptors in both stroma and glands. On the other hand, oestrogen receptors are expressed in endometrial polyps. Conclusions Endometrial polyps in menopausal patients receiving HRT respond only to oestrogens but not to progestins. The unopposed oestrogenic action on polyps may favour the development of premalignant hyperplasia and carcinoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Histopathology and steroid receptors in endometrial polyps of postmenopausal patients under hormone‐replacement therapy

Maia¹,

Maltez²,

Calmon³

et al. 1998

Gynaecol Endoscopy

View full text Add to dashboard Cite

show abstract

“…However, a preserved induction of 17phydroxy-steroid-dehydrogenase activity by progestins has been observed in some endometrial carcinomas (Vihko et al 1991). PgR are in general lost earlier and more frequently than ER in endometrial carcinomas (Nyholm et al 1992). Thus neoplastic transformation of endometrial epithelial cells seems to be associated with alteration in ER and PgR hnction leading to a loss of PgR and ER with increasing dedifferentiation.…”

Section: The Endometrium a Target Tissue For Hormone Actionsmentioning

confidence: 94%

“…ER and PgR in the endometrium. ER and PgR are present, however inconstantly, in epithelial and stromal cells of normal human endometrial tissue and are also present in most adenomatous hyperplasias and endometrial carcinomas (Bergeron et al 1988;Snidjers et al 1992;VI;Nyholm et al 1992). Progesterone induces a down-regulation of ER and PgR in normal cyclic endometrial epithelial cells (Tseng 1979;Satyaswaroop et al 1982;Vihko et al 1991;Roy 1992).…”

Section: The Endometrium a Target Tissue For Hormone Actionsmentioning

confidence: 99%

ABH and related histo‐blood group antigens in normal & malignant human endometrium in relation to genetic and hormonal factors

Skovlund

1997

APMIS

View full text Add to dashboard Cite

“…A previous study also showed high ER and PR content in epithelium and stromal cells of simple and complex hyperplasia [2]. In atypical complex hyperplasia and endometrioid adenocarcinoma, however, the receptor content was significantly lower compared with that of normal proliferative or hyperplastic endometrium [2,17,19]. A few studies have demonstrated nuclear staining for AR in normal glands, endometrial stromal cells, and in endometrioid adenocarcinomas [3].…”

Section: Discussionmentioning

confidence: 92%

Expression of androgen receptors in benign and malignant endometrial stromal neoplasms

et al. 2004

View full text Add to dashboard Cite

Several studies have shown that endometrial stromal neoplasms express estrogen and progesterone receptors (ER, PR). To our knowledge, the presence or absence of androgen receptors (AR) in these rare uterine neoplasms has not been investigated. Tumors ( n=20)-3 endometrial stromal nodules, 14 low-grade endometrial stromal sarcomas (ESS, low grade), and 3 high-grade endometrial sarcomas (undifferentiated endometrial sarcoma, UES)-were studied. Immunohistochemical analyses for ER, PR, and AR were performed on formalin-fixed, paraffin-embedded archival material. Positive immunoreactions for ER and PR were observed in 14 (70%) and 17 (85%) cases, respectively. Furthermore, 9 cases (45%) were positive for AR. Among 17 ESS and UES cases, 7 (41%) revealed positivity for AR. Two of three benign stromal nodules were also positive for AR. Moreover, one of the three high-grade sarcomas (undifferentiated endometrial sarcoma) was negative for both ER and PR, but showed positive reaction for AR. In summary, ARs are expressed in 45% of endometrial stromal neoplasms. In addition to determination of ER and PR, the results of immunohistochemical examination of AR in these rare uterine tumors may have some impact on the postoperative management of the patients.

show abstract

Biochemical and immunohistochemical estrogen and progesterone receptors in adenomatous hyperplasia and endometrial carcinoma: Correlations with stage and other clinicopathologic features

Cited by 7 publications

References 0 publications

Histopathology and steroid receptors in endometrial polyps of postmenopausal patients under hormone‐replacement therapy

Histopathology and steroid receptors in endometrial polyps of postmenopausal patients under hormone‐replacement therapy

ABH and related histo‐blood group antigens in normal & malignant human endometrium in relation to genetic and hormonal factors

Expression of androgen receptors in benign and malignant endometrial stromal neoplasms

Contact Info

Product

Resources

About